• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脑出血凝血功能障碍的逆转。

Coagulopathy reversal in intracerebral haemorrhage.

机构信息

Neurology, University of California Irvine Medical Center, Orange, California, USA.

Medicine, University of California Irvine Medical Center, Orange, California, USA.

出版信息

Stroke Vasc Neurol. 2020 Feb 20;5(1):29-33. doi: 10.1136/svn-2019-000274. eCollection 2020.

DOI:10.1136/svn-2019-000274
PMID:32411405
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7213499/
Abstract

As intracerebral hemorrahge becomes more frequent as a result of an aging population with greater comorbidities, rapid identification and reversal of precipitators becomes increasingly paramount. The aformentioned population will ever more likely be on some form of anticoagulant therapy. Understanding the mechanisms of these agents and means by which to reverse them early on is critical in managing the acute intracerebral hemorrhage.

摘要

随着人口老龄化和合并症增多,颅内出血的发病率越来越高,因此快速识别和逆转诱因变得至关重要。上述人群更有可能接受某种形式的抗凝治疗。了解这些药物的作用机制以及早期逆转它们的方法对于急性颅内出血的治疗至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f48/7213499/ca3cb2a4b153/svn-2019-000274f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f48/7213499/ca3cb2a4b153/svn-2019-000274f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f48/7213499/ca3cb2a4b153/svn-2019-000274f01.jpg

相似文献

1
Coagulopathy reversal in intracerebral haemorrhage.脑出血凝血功能障碍的逆转。
Stroke Vasc Neurol. 2020 Feb 20;5(1):29-33. doi: 10.1136/svn-2019-000274. eCollection 2020.
2
Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate.维生素 K 拮抗剂相关颅内出血应用血浆或 4 因子凝血酶原复合物浓缩物治疗的死亡率。
Thromb Haemost. 2014 Feb;111(2):233-9. doi: 10.1160/TH13-07-0536. Epub 2013 Oct 24.
3
Reversal of direct oral anticoagulants.直接口服抗凝剂的逆转
Br J Hosp Med (Lond). 2017 Mar 2;78(3):165-169. doi: 10.12968/hmed.2017.78.3.165.
4
Correction of coagulopathy in warfarin associated cerebral hemorrhage.华法林相关脑出血中凝血障碍的纠正
Curr Opin Crit Care. 2009 Apr;15(2):87-92. doi: 10.1097/MCC.0b013e3283269e4d.
5
Reversal of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) in the Presence of Major Life-Threatening Bleeding.在发生严重危及生命的出血时逆转非维生素K拮抗剂口服抗凝药(NOACs)的作用
Ann Emerg Med. 2017 Dec;70(6):944-945. doi: 10.1016/j.annemergmed.2017.08.037.
6
Intracerebral hemorrhage in patients receiving oral anticoagulation therapy.接受口服抗凝治疗患者的脑出血
J Intensive Care Med. 2015 Feb;30(2):63-78. doi: 10.1177/0885066613488732. Epub 2013 May 20.
7
Medical Treatment for Spontaneous Anticoagulation-Related Intracerebral Hemorrhage in the Netherlands.荷兰自发性抗凝相关脑出血的医学治疗
J Stroke Cerebrovasc Dis. 2017 Jul;26(7):1427-1432. doi: 10.1016/j.jstrokecerebrovasdis.2017.03.019. Epub 2017 Apr 12.
8
Controversies of anticoagulation reversal in life-threatening bleeds.危及生命出血时抗凝逆转的争议
J Pharm Pract. 2010 Jun;23(3):217-25. doi: 10.1177/0897190010362168. Epub 2010 Apr 13.
9
Warfarin reversal.华法林逆转。
J Clin Pathol. 2004 Nov;57(11):1132-9. doi: 10.1136/jcp.2003.008904.
10
Reversal agents for non-vitamin K antagonist oral anticoagulants.非维生素 K 拮抗剂口服抗凝剂的逆转剂。
Nat Rev Cardiol. 2018 May;15(5):273-281. doi: 10.1038/nrcardio.2017.223. Epub 2018 Jan 18.

引用本文的文献

1
Clinical utility of consecutive volume scanning dual-energy CT in differentiating hemorrhage from contrast staining in ischemic stroke patients.连续容积扫描双能量CT在鉴别缺血性脑卒中患者出血与对比剂染色中的临床应用价值
J Appl Clin Med Phys. 2025 Sep;26(9):e70209. doi: 10.1002/acm2.70209.
2
Specific Reversal Agents for Direct Oral Anticoagulants in Acute Stroke.直接口服抗凝剂在急性脑卒中的特异性逆转剂。
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241279545. doi: 10.1177/10760296241279545.
3
Reversal and resumption of anticoagulants in patients with anticoagulant-associated intracerebral hemorrhage.

本文引用的文献

1
Effect of Recombinant Activated Coagulation Factor VII on Hemorrhage Expansion Among Patients With Spot Sign-Positive Acute Intracerebral Hemorrhage: The SPOTLIGHT and STOP-IT Randomized Clinical Trials.重组活化凝血因子VII对斑点征阳性急性脑出血患者出血扩大的影响:SPOTLIGHT和STOP-IT随机临床试验
JAMA Neurol. 2019 Dec 1;76(12):1493-1501. doi: 10.1001/jamaneurol.2019.2636.
2
Higher Incidence of Ischemic Stroke in Patients Taking Novel Oral Anticoagulants.新型口服抗凝剂治疗患者缺血性脑卒中发生率较高。
Stroke. 2018 Dec;49(12):2851-2856. doi: 10.1161/STROKEAHA.118.022636.
3
Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs).
抗凝相关脑出血患者抗凝剂的逆转与恢复
Eur J Med Res. 2024 Apr 24;29(1):252. doi: 10.1186/s40001-024-01816-5.
4
Andexanet Alfa to Reverse the Effect of Factor Xa Inhibitors in Intracranial Hemorrhage.Andexanet Alfa 逆转颅内出血患者的 Xa 因子抑制剂的作用。
CNS Drugs. 2023 Jun;37(6):477-487. doi: 10.1007/s40263-023-01006-7. Epub 2023 May 3.
5
Intraparenchymal Hematoma With Significant Mass Effect Treated With Factor Eight Inhibitor Bypass Activity.采用凝血因子 VIII 抑制物旁路活性治疗的具有显著占位效应的脑实质内血肿
Cureus. 2022 Nov 11;14(11):e31385. doi: 10.7759/cureus.31385. eCollection 2022 Nov.
6
Clinical and Imaging Characteristics in Patients with SARS-CoV-2 Infection and Acute Intracranial Hemorrhage.新型冠状病毒2019感染合并急性颅内出血患者的临床及影像学特征
J Clin Med. 2020 Aug 6;9(8):2543. doi: 10.3390/jcm9082543.
非维生素 K 拮抗剂口服抗凝剂(NOACs)的药代动力学药物相互作用。
Pharmacol Res. 2018 Sep;135:60-79. doi: 10.1016/j.phrs.2018.07.016. Epub 2018 Jul 21.
4
Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data.非瓣膜性心房颤动患者中阿哌沙班与华法林的安全性和有效性比较:来自日本行政索赔数据的倾向评分匹配分析。
Curr Med Res Opin. 2018 Sep;34(9):1627-1634. doi: 10.1080/03007995.2018.1478282. Epub 2018 May 30.
5
Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin.比较直接口服抗凝剂或华法林相关的脑出血。
Neurology. 2018 Mar 27;90(13):e1143-e1149. doi: 10.1212/WNL.0000000000005207. Epub 2018 Feb 28.
6
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.利伐沙班或阿哌沙班相关大出血的凝血酶原复合物浓缩物管理:一项队列研究。
Blood. 2017 Oct 12;130(15):1706-1712. doi: 10.1182/blood-2017-05-782060. Epub 2017 Aug 23.
7
Direct oral anticoagulant- vs vitamin K antagonist-related nontraumatic intracerebral hemorrhage.直接口服抗凝剂与维生素K拮抗剂相关的非创伤性脑出血
Neurology. 2017 Sep 12;89(11):1142-1151. doi: 10.1212/WNL.0000000000004362. Epub 2017 Aug 16.
8
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.达比加群酯逆转剂依达鲁珠单抗:全队列分析。
N Engl J Med. 2017 Aug 3;377(5):431-441. doi: 10.1056/NEJMoa1707278. Epub 2017 Jul 11.
9
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.非瓣膜性心房颤动且既往有卒中和短暂性脑缺血发作患者中应用阿哌沙班、达比加群和利伐沙班与华法林的有效性和安全性。
Stroke. 2017 Aug;48(8):2142-2149. doi: 10.1161/STROKEAHA.117.017474. Epub 2017 Jun 27.
10
Outcome of intracerebral hemorrhage associated with different oral anticoagulants.不同口服抗凝剂相关脑出血的结局
Neurology. 2017 May 2;88(18):1693-1700. doi: 10.1212/WNL.0000000000003886. Epub 2017 Apr 5.